Sec Form 3 Filing - Lesser Brian Andrew @ Forma Therapeutics Holdings, Inc. - 2021-11-15

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Lesser Brian Andrew 2. Issuer Name and Ticker or Trading Symbol Forma Therapeutics Holdings, Inc. [ FMTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP, Commercial Officer (Last) (First) (Middle) C/O FORMA THERAPEUTICS HOLDINGS, INC., 300 NORTH BEACON STREET, SUITE 501 3. Date of Earliest Transaction (MM/DD/YY) 11/15/2021 (Street) WATERTOWN, MA02472 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12,100( 1 ) D Common Stock 9,330( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 5.05 ( 2 ) 11/20/2029 Common Stock 32,987 D Stock Option (Right to Buy) $ 5.05 ( 3 ) 11/20/2029 Common Stock 17,533 D Stock Option (Right to Buy) $ 5.43 ( 4 ) 02/11/2030 Common Stock 46,756 D Stock Option (Right to Buy) $ 20 ( 5 ) 06/17/2030 Common Stock 46,756 D Stock Option (Right to Buy) $ 38.61 ( 6 ) 02/25/2031 Common Stock 36,850 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Lesser Brian Andrew C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET, SUITE 501 WATERTOWN, MA02472 SVP, Commercial Officer Signatures /s/ Jeannette Potts, as Attorney-in-Fact 11/19/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. ( 2 )25% of the shares shall vest on the first anniversary of September 23, 2019, and the remaining 75% of such shares shall vest in thirty-six (36) equal monthly installments; provided that the Reporting Person remains continuously engaged by the Company on each such date. ( 3 )25% of the shares shall vest on the first anniversary of November 21, 2019, and the remaining 75% of such shares shall vest in thirty-six (36) equal monthly installments; provided that the Reporting Person remains continuously engaged by the Company on each such date. ( 4 )25% of the shares shall vest on the first anniversary of February 12, 2020, and the remaining 75% of such shares shall vest in thirty-six (36) equal monthly installments; provided that the Reporting Person remains continuously engaged by the Company on each such date. ( 5 )25% of the shares shall vest on the first anniversary of June 18, 2020, and the remaining 75% of such shares shall vest in thirty-six (36) equal monthly installments; provided that the Reporting Person remains continuously engaged by the Company on each such date. ( 6 )25% of the shares shall vest on the first anniversary of February 22, 2021, and the remaining 75% of such shares shall vest in thirty-six (36) equal monthly installments; provided that the Reporting Person remains continuously engaged by the Company on each such date.

Remarks: Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.